2022
Factors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable Analysis
King ALO, Lee V, Mirza FN, Jairam V, Yang DX, Yu JB, Park HS, Girardi M, Wilson LD, An Y, Wilson L. Factors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable Analysis. Cureus 2022, 14: e28043. PMID: 36120198, PMCID: PMC9474264, DOI: 10.7759/cureus.28043.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaNationwide Emergency Department SampleHospital mortalityMycosis fungoides patientsMycosis fungoidesMF patientsBackground Mycosis fungoidesIn-Hospital MortalitySpecific clinical factorsMultivariable logistic regressionEmergency Department SampleT-cell lymphomaUnderstanding of patientsSézary syndromeClinical factorsIndolent courseMultivariable analysisSurvival outcomesFemale sexHospital characteristicsAdvanced ageEmpirical managementPatientsMF casesGreater risk
2020
Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides.
Hu JK, Carlson K, Girardi M. Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides. The Yale Journal Of Biology And Medicine 2020, 93: 41-44. PMID: 32226334, PMCID: PMC7087069.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMycosis fungoidesLocal immunotherapyIntralesional injectionSide effectsAssociated systemic side effectsSkin-homing T cellsEarly-stage mycosis fungoidesTreatment of MFCases of MFGeneralized side effectsStage mycosis fungoidesT-cell lymphomaSystemic side effectsRecombinant interferon α2bImprovement of diseaseSystemic therapyRecalcitrant lesionsMF patientsTherapeutic optionsMalignant CD4Intramuscular injectionMF lesionsSystemic administrationSubsequent dosing